Six amino acid residues in a 1200 å2 interface mediate binding of factor viii to an IgG4ê inhibitory antibody

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Lin, Jasper C ^a,b,f   Ettinger, Ruth A ^a   Schuman, Jason T ^c   Zhang, Ai Hong ^d   Wamiq Adhami, Muhammad ^e   Nguyen, Phuong Cac T ^a   Nakaya Fletcher, Shelley M ^a   Puranik, Komal ^a   Thompson, Arthur R ^a,b   Pratt, Kathleen P ^a,b,d  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GE Healthcare   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 KAPPA; MONOCLONAL ANTIBODY; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8;

AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BETA CHAIN; BINDING AFFINITY; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; MOLECULAR RECOGNITION; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE; THERMODYNAMICS; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL;

MURINAE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; BINDING SITES; EPITOPES; FACTOR VIII; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; SURFACE PLASMON RESONANCE; THERMODYNAMICS; VON WILLEBRAND FACTOR;

EID: 84921631309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116577     Document Type: Article

References (54)

1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, et al. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594-598. doi: 10.1016/0140-6736(92) 90874-3 PMID: 1347102
2. Lusher JM, Lee CA, Kessler CM, Bedrosian CL (2003) The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9: 38-49. doi: 10.1046/j.1365-2516.2003.00708.x PMID: 12558777
3. Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, et al. (1998) Factor VIII inhibitors in mild and mod-erate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 79: 762-766. doi: PMID: 9569189
4. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, et al. (2007) Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 109: 1870-1877. doi: 10.1182/blood-2006-06-029850 PMID: 17047148
5. Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, et al. (2006) Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 12 Suppl 6: 1-7. doi: 10.1111/j.1365-2516.2006.01359.x PMID: 17123387
6. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 328: 453-459. doi: 10.1056/ NEJM199302183280701 PMID: 8421474
7. Qian J, Borovok M, Bi L, Kazazian HH Jr, Hoyer LW (1999) Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81: 240-244. doi: PMID: 10063999
8. Wu H, Reding M, Qian J, Okita DK, Parker E, et al. (2001) Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 85: 125-133. doi: PMID: 11204564
9. Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, et al. (2004) Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 92: 522-528. doi: 10.1267/THRO04090522 PMID: 15351848
10. Liu M, Murphy ME, Thompson AR (1998) A domain mutations in 65 haemophilia A families and molecular modelling of dysfunctional factor VIII proteins. Br J Haematol 103: 1051-1060. doi: 10.1046/j.1365-2141.1998.01122.x PMID: 9886318
11. Fuentes-Prior P, Fujikawa K, Pratt KP (2002) New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci 3: 313-339. doi: 10.2174/1389203023380639 PMID: 12188899
12. Thompson AR (2003) Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 29: 11-22. doi: 10.1055/s-2003-37935 PMID: 12640560
13. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS (1990) A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor. Thromb Haemost 63: 403-406. doi: PMID: 2119526
14. Saenko EL, Scandella D (1995) A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 270: 13826-13833. doi: 10.1074/jbc.270.23.13826 PMID: 7775440
15. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P (2001) Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 97: 169-174. doi: 10.1182/blood.V97.1.169 PMID: 11133757
16. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D (1994) A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 269: 11601-11605. doi: PMID: 7512568
17. Shima M, Yoshioka A, Nakai H, Tanaka I, Sawamoto Y, et al. (1991) Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor. Int J Hematol 54: 515-522. doi: PMID: 1724391
18. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, et al. (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86: 1811-1819. doi: PMID: 7544643
19. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P (2007) Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 110: 4234-4242. doi: 10.1182/blood-2007-06-096842 PMID: 17848617
20. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P (2008) Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 112: 1151-1153. doi: 10.1182/blood-2008-01-132639 PMID: 18495957
21. Walter JD, Werther RA, Brison CM, Cragerud RK, Healey JF, et al. (2013) Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. Blood 122: 4270-4278. doi: PMID: 24085769
22. Walter JD, Werther RA, Polozova MS, Pohlman J, Healey JF, et al. (2013) Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies. J Biol Chem 288: 9905-9914. doi: 10.1074/jbc.M112.424564 PMID: 23417672
23. Sevy AM, Healey JF, Deng W, Spiegel PC, Meeks SL, et al. (2013) Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry. J Thromb Haemost 11: 2128-2136. doi: 10.1111/jth.12433 PMID: 24152306
24. Nguyen PC, Lewis KB, Ettinger RA, Schuman JT, Lin JC, et al. (2014) High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. Blood 123: 2732-2739. doi: PMID: 24591205
25. Lubin IM, Healey JF, Scandella D, Runge MS, Lollar P (1994) Elimination of a major inhibitor epitope in factor VIII. J Biol Chem 269: 8639-8641. doi: PMID: 7510693
26. Kuwabara I, Maruyama H, Kamisue S, Shima M, Yoshioka A, et al. (1999) Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. J Immunol Methods 224: 89-99. doi: 10.1016/S0022-1759(99)00012-5 PMID: 10357210
27. Voorberg J, van den Brink EN (2000) Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII. Semin Thromb Hemost 26: 143-150. doi: 10.1055/s-2000-9816 PMID: 10919406
28. Ansong C, Miles SM, Fay PJ (2006) Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12. J Thromb Haemost 4: 842-847. doi: 10.1111/j.1538-7836.2006.01831.x PMID: 16634755
29. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, et al. (2007) The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost 5: 512-519. doi: 10.1111/j.1538-7836. 2006.02373.x PMID: 17181826
30. Kessel C, Kreuz W, Klich K, Becker-Peters K, Vorpahl F, et al. (2009) Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. ChemMedChem 4: 1364-1370. doi: 10.1002/ cmdc.200900023 PMID: 19533722
31. Griffiths AE, Wang W, Hagen FK, Fay PJ (2011) Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction. J Thromb Haemost 9: 1534-1540. doi: 10.1111/j.1538-7836.2011.04397.x PMID: 21668738
32. Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, et al. (1998) Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92: 496-506. doi: PMID: 9657749
33. Spiegel PC Jr., Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP (2001) Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.Blood 98: 13-19. doi: 10.1182/blood.V98.1.13 PMID: 11418455
34. Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, et al. (2009) Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Mol Immunol 47: 290-297. doi: 10.1016/j.molimm.2009.09.021 PMID: 19811836
35. Dimitrov JD, Roumenina LT, Plantier JL, Andre S, Saboulard D, et al. (2010) A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. J Thromb Haemost 8: 1524-1531. doi: 10.1111/j.1538-7836.2010.03878.x PMID: 20374449
36. Deinum J, Gustavsson L, Gyzander E, Kullman-Magnusson M, Edstrom A, et al. (2002) A thermodynamic characterization of the binding of thrombin inhibitors to human thrombin, combining biosensor technology, stopped-flow spectrophotometry, and microcalorimetry. Anal Biochem 300: 152-162. doi: 10.1006/abio.2001.5454 PMID: 11779106
37. Roos H, Karlsson R, Nilshans H, Persson A (1998) Thermodynamic analysis of protein interactions with biosensor technology. J Mol Recognit 11: 204-210. doi: 10.1002/(SICI)1099-1352(199812)11:1/ 6<204::AID-JMR424>3.0.CO;2-T PMID: 10076841
38. Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P (2004) Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 104: 704-710. doi: 10.1182/blood-2003-11-3891 PMID: 15073030
39. Sandberg H, Kannicht C, Stenlund P, Dadaian M, Oswaldsson U, et al. (2012) Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 130: 808-817. doi: 10.1016/j.thromres.2012.08.311 PMID: 23010293
40. Dimitrov JD, Christophe OD, Kang J, Repesse Y, Delignat S, et al. (2012) Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. Biochemistry 51: 4108-4116. doi: 10.1021/ bi300232d PMID: 22559004
41. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, et al. (1975) Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612. doi: PMID: 1198543
42. Takeshima K, Smith C, Tait J, Fujikawa K (2003) The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 89: 788-794. doi: 10.1267/THRO03050788 PMID: 12719774
43. Cunningham BC, Wells JA (1993) Comparison of a structural and a functional epitope. J Mol Biol 234: 554-563. doi: 10.1006/jmbi.1993.1611 PMID: 7504735
44. Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267: 383-386. doi: 10.1126/science.7529940 PMID: 7529940
45. DeLano WL, Ultsch MH, de Vos AM, Wells JA (2000) Convergent solutions to binding at a protein-protein interface. Science 287: 1279-1283. doi: 10.1126/science.287.5456.1279 PMID: 10678837
46. Pearce KH Jr., Potts BJ, Presta LG, Bald LN, Fendly BM, et al. (1997) Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites. J Biol Chem 272: 20595-20602. doi: 10.1074/jbc.272.33.20595 PMID: 9252374
47. Tummino PJ, Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47: 5481-5492. doi: 10.1021/bi8002023 PMID: 18412369
48. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, et al. (1994) Dissociation rate of anti-body-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol 153: 449-459. doi: PMID: 7515931
49. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739. doi: 10.1038/nrd2082 PMID: 16888652
50. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, et al. (1999) Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 402: 439-442. doi: 10.1038/46601 PMID: 10586887
51. Pace CN, Shirley BA, McNutt M, Gajiwala K (1996) Forces contributing to the conformational stability of proteins. FASEB J 10: 75-83. doi: PMID: 8566551
52. Fulcher CA, de Graaf Mahoney S, Zimmerman TS (1987) FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69: 1475-1480. doi: PMID: 2436689
53. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM (1993) Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82: 2452-2461. doi: PMID: 7691260
54. Lewis DA, Pound ML, Ortel TL (2003) Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Thromb Haemost 89: 795-802. doi: 10.1267/THRO03050795 PMID: 12719775